Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
Listen to Joleen Hubbard, MD, and John L. Marshall, MD, discuss the use of key later-line treatment options for patients with mCRC, including optimal treatment sequencing and dosing and key adverse events.
Decera Clinical Education Oncology Podcast · John Marshall MD, Joleen Hubbard MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:
- Key data supporting the clinical use of these agents
- Optimal sequencing and timing of use
- Dosing considerations
- Key adverse events
Presenters:
Joleen Hubbard, MD
Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC
Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Link to full program: BITLY NEEDED
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.